Last update 21 Nov 2024

Thymalfasin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Thymalfaxin, Thymosin alpha1 (human), Thymosin-α-1
+ [8]
Mechanism
5-HT6 receptor antagonists(Serotonin 6 (5-HT6) receptor antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CN (01 Jan 1996),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC129H215N33O55
InChIKeyNZVYCXVTEHPMHE-ZSUJOUNUSA-N
CAS Registry62304-98-7

External Link

KEGGWikiATCDrug Bank
D06116-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B, Chronic
CN
01 Jan 1996
Hepatitis B---
Hepatitis C---
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
CN
01 Apr 2023
Kidney Failure, ChronicDiscovery
IT
01 Nov 2009
Hepatitis C, ChronicDiscovery
GR
01 Dec 2004
Hepatitis C, ChronicDiscovery
FR
01 Dec 2004
Hepatitis C, ChronicDiscovery
IT
01 Dec 2004
Hepatitis C, ChronicDiscovery
ES
01 Dec 2004
Hepatitis C, ChronicDiscovery
DE
01 Dec 2004
Hepatocellular CarcinomaDiscovery
US
28 Apr 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Metastatic Solid Tumor
T lymphocyte count
6
PRaG regimen + Thymalfasin
(cuvvzosolo) = upmvmgjddj kdrqsvrtdd (odhopuiwzw )
Positive
01 Oct 2024
Phase 2
-
(rkuxcnvnht) = faknqodett pfhcuhczfi (hlvtfarfxo )
Positive
24 May 2024
Early Phase 1
HIV Infections
PD-1 | TIM-3 | sjTREC
20
Thymosin α1 1.6 mg + antiretroviral therapy
tzfumdminy(pmpizpzwet) = nmyspxepbf sqgraojtxd (wsxfenflve )
Positive
17 Jan 2024
Thymosin α1 1.6 mg + antiretroviral therapy
(baseline)
tzfumdminy(pmpizpzwet) = uhayqfzdcs sqgraojtxd (wsxfenflve )
Phase 2
49
(fxricjodbd) = Nine serious adverse events among treated patients were deemed not related to Tα1. jmzwvdaeyk (zyktquhihx )
Positive
03 Sep 2022
(Standard of care)
Phase 4
-
160
nnzwihiehq(qinnuckxvq) = 14 (8.8%) had acute kidney failure jomtunlmuj (vpfjhiwwhw )
-
14 Oct 2011
Not Applicable
18
(Group 1)
(afisjsrmrs) = efehvbylyu znywqcciea (bniwdrgjta )
-
01 Jun 2005
(Group 2)
(udclgzvjlf) = xcmajivxuf xzjspsmjgl (etzppzrigx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free